fromNature
19 hours agoEconomic reform can save antibiotic innovation
Antibiotic development is long and expensive, yet antibiotics are used for short durations and sold at relatively low prices. Newly developed antibiotics are often also reserved for use as a last resort, to protect the drugs' efficacy. This combination of factors makes it difficult for a company to recoup their investment, and has led to an exodus of organizations and scientific talent from antibiotic research and development. The pipeline of drugs has been reduced to a trickle, and deaths resulting from antibiotic resistance are increasing.
European startups












